Skip to main content

Dr. Reddy's Laboratories Ltd

corporate_fare Company Profile

Dr. Reddy's Laboratories Ltd

RDY·NYSE·Life Sciences·CIK 0001135951

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Ltd (NYSE:RDY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for RDY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for RDY spans 6-K, 144, 20-F.

Recent high-impact activity:

  • Dr. Reddy's Secures Brazil Approval for Generic Semaglutide Injection
  • FDA Approves First Generic Rival to Gilead's Yeztugo
  • Dr. Reddy's CEO Erez Israeli Notices Sale of 460,726 ADRs (~$6.5M)
  • Dr. Reddy's Q2 FY2026 Profit Falls 36% on North America Price Erosion
  • Third USFDA Form 483 in a Week Hits Dr. Reddy's, This Time at FTO-9 Facility

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$3.58B
Net Income
$452M
Diluted EPS
$0.55
Op. Cash Flow
$607M
Free Cash Flow
$358M
Gross Profit
$1.89B
Operating Income
$539M
Cash & Equivalents
$164M
Total Debt
$194M
Debt / Equity
0.05×
Net Margin
12.6%
Shares Outstanding
832M sh
Source: 20-F · filed 2026-05-29 · accession 0001575872-26-000381

Short Interest & Short Volume

7.81 days to cover

FINRA reported short interest of 25,297,771 shares in RDY as of the October 30, 2026 settlement, a 3.2% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 58.7% of RDY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)25,297,771 shares as of October 30, 2026
Change vs prior period▼ 3.2%
Days to cover7.81 at avg daily volume of 3,240,176
Daily short volume (FINRA facilities)58.7% of 575,023 shares on November 20, 2026
5-day average short volume53.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

RDY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with R →
$15 +0.74% today
52-week range · as of 2026-11-05 $11.36 – $15.67
Market cap
$12.41B
Volume
1.7M (0.6× avg)
3-mo avg 2.7M
Live data · 2026-11-22 00:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RDY - Latest Insights

RDY
Nov 05, 2026, 6:06 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.75
Real-time Price: $15.00 info
Change: +$0.250 (+2%) info
Market Cap: $12.413B info
RDY
Nov 03, 2026, 1:09 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $14.38
Real-time Price: $15.00 info
Change: +$0.624 (+4%) info
Market Cap: $12.413B info
RDY
Nov 02, 2026, 12:25 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $15.00 info
Change: +$0.905 (+6%) info
Market Cap: $12.413B info
RDY
Oct 23, 2026, 12:22 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.22
Real-time Price: $15.00 info
Change: +$1.79 (+14%) info
Market Cap: $12.413B info
RDY
Oct 14, 2026, 12:43 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.82
Real-time Price: $15.00 info
Change: +$2.19 (+17%) info
Market Cap: $12.413B info
RDY
Oct 08, 2026, 9:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.27
Real-time Price: $15.00 info
Change: +$2.73 (+22%) info
Market Cap: $12.413B info
RDY
Sep 18, 2026, 6:24 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.35
Real-time Price: $15.00 info
Change: +$2.65 (+21%) info
Market Cap: $12.413B info
RDY
Sep 14, 2026, 6:35 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $11.90
Real-time Price: $15.00 info
Change: +$3.10 (+26%) info
Market Cap: $12.413B info
RDY
Aug 17, 2026, 6:40 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $12.45
Real-time Price: $15.00 info
Change: +$2.55 (+20%) info
Market Cap: $12.413B info
RDY
Aug 03, 2026, 6:24 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $11.93
Real-time Price: $15.00 info
Change: +$3.07 (+26%) info
Market Cap: $12.413B info
RDY
Jul 29, 2026, 2:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $11.80
Real-time Price: $15.00 info
Change: +$3.20 (+27%) info
Market Cap: $12.413B info
RDY
Jul 22, 2026, 1:36 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $11.60
Real-time Price: $15.00 info
Change: +$3.40 (+29%) info
Market Cap: $12.413B info
RDY
Jul 22, 2026, 8:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $12.19
Real-time Price: $15.00 info
Change: +$2.81 (+23%) info
Market Cap: $12.413B info
RDY
Jul 15, 2026, 9:45 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $12.88
Real-time Price: $15.00 info
Change: +$2.12 (+16%) info
Market Cap: $12.413B info
RDY
Jul 09, 2026, 6:18 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.65
Real-time Price: $15.00 info
Change: +$1.35 (+10%) info
Market Cap: $12.413B info
RDY
Jun 30, 2026, 1:36 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.53
Real-time Price: $15.00 info
Change: +$0.470 (+3%) info
Market Cap: $12.413B info
RDY
Jun 26, 2026, 11:59 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.59
Real-time Price: $15.00 info
Change: -$0.590 (-4%) info
Market Cap: $12.413B info
RDY
Jun 22, 2026, 6:27 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.41
Real-time Price: $15.00 info
Change: +$1.59 (+12%) info
Market Cap: $12.413B info
RDY
Jun 15, 2026, 6:10 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.30
Real-time Price: $15.00 info
Change: +$1.70 (+13%) info
Market Cap: $12.413B info
RDY
May 29, 2026, 5:12 PM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $13.63
Real-time Price: $15.00 info
Change: +$1.37 (+10%) info
Market Cap: $12.413B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets